BidaskClub downgraded shares of Integra Lifesciences (NASDAQ:IART) from a buy rating to a hold rating in a report published on Tuesday, BidAskClub reports.

Several other equities research analysts have also recently issued reports on the stock. ValuEngine cut shares of Acceleron Pharma from a strong-buy rating to a buy rating in a research report on Thursday, April 18th. Zacks Investment Research raised shares of Hanmi Financial from a sell rating to a hold rating in a research report on Thursday, June 20th. Finally, Oppenheimer lifted their price objective on shares of Chipotle Mexican Grill from $400.00 to $525.00 and gave the stock an underperform rating in a research report on Thursday, April 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $58.64.

Shares of IART stock opened at $54.23 on Tuesday. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.86 and a quick ratio of 1.86. Integra Lifesciences has a 52 week low of $42.14 and a 52 week high of $66.41. The stock has a market cap of $4.64 billion, a PE ratio of 22.41, a PEG ratio of 1.65 and a beta of 1.07. The firm has a 50 day simple moving average of $51.53.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, April 24th. The life sciences company reported $0.65 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.04. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The company had revenue of $359.69 million during the quarter, compared to analysts’ expectations of $361.12 million. During the same quarter last year, the company posted $0.58 EPS. The firm’s revenue was up .7% compared to the same quarter last year. On average, sell-side analysts predict that Integra Lifesciences will post 2.7 earnings per share for the current fiscal year.

In related news, COO Glenn Coleman sold 3,650 shares of Integra Lifesciences stock in a transaction on Friday, June 28th. The shares were sold at an average price of $55.00, for a total transaction of $200,750.00. Following the sale, the chief operating officer now directly owns 25,160 shares in the company, valued at approximately $1,383,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christian S. Schade sold 15,658 shares of Integra Lifesciences stock in a transaction on Friday, May 10th. The stock was sold at an average price of $51.56, for a total transaction of $807,326.48. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in IART. BlackRock Inc. raised its stake in Integra Lifesciences by 3.2% during the 4th quarter. BlackRock Inc. now owns 6,730,304 shares of the life sciences company’s stock worth $303,536,000 after acquiring an additional 210,960 shares in the last quarter. Raymond James & Associates raised its stake in Integra Lifesciences by 6.4% during the 4th quarter. Raymond James & Associates now owns 56,648 shares of the life sciences company’s stock worth $2,555,000 after acquiring an additional 3,412 shares in the last quarter. Blueshift Asset Management LLC acquired a new stake in Integra Lifesciences during the 4th quarter worth $230,000. Northern Trust Corp raised its stake in Integra Lifesciences by 1.1% during the 4th quarter. Northern Trust Corp now owns 607,714 shares of the life sciences company’s stock worth $27,409,000 after acquiring an additional 6,799 shares in the last quarter. Finally, NumerixS Investment Technologies Inc raised its stake in Integra Lifesciences by 100.1% during the 4th quarter. NumerixS Investment Technologies Inc now owns 2,801 shares of the life sciences company’s stock worth $124,000 after acquiring an additional 1,401 shares in the last quarter. Hedge funds and other institutional investors own 82.27% of the company’s stock.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

See Also: What are gap-up stocks?

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.